Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

Go back to Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
(NASDAQ: NTRA) Delayed: 391.86 -21.52 (5.21%)
Previous Close $413.38    52 Week High $13.80 
Open $408.47    52 Week Low $6.52 
Day High $416.00    P/E N/A 
Day Low $390.78    EPS $0.00 
Volume 686,032